How PhaseV is Revolutionizing Clinical Trials Using AI to Accelerate Drug Development

In the ever-evolving world of medicine, the path from a drug or medical device’s inception to its approval and availability in the market is a long and costly journey. Clinical trials are at the heart of this process, often taking years and substantial financial investments. However, PhaseV, an innovative AI software company, is changing the game. Co-founded by Dr. Raviv Pryluk, PhaseV is focused on leveraging artificial intelligence to streamline clinical development and reduce the high failure rates of clinical trials. Recently named one of the Top 10 Israeli startups to watch in 2025, PhaseV’s approach offers hope to the pharmaceutical and biotech industries, promising more efficient, successful, and cost-effective clinical trials.

PhaseV’s AI-Powered Solution to Drug Development Challenges

Dr. Raviv Pryluk, CEO and Co-Founder of PhaseV, sheds light on the considerable challenges faced during clinical development. According to him, this phase remains the most expensive and time-consuming aspect of bringing a drug or medical device to market. PhaseV, which operates out of Tel Aviv and Boston, is aiming to address this by using AI to enhance the decision-making process, making clinical trials more effective while reducing their risk of failure. By providing tools that help sponsors, pharmaceutical companies, biotech firms, and Contract Research Organizations (CROs) make better choices, PhaseV is taking steps to prevent the frequent pitfalls that contribute to the 90% failure rate of clinical trials.

Since its founding in 2023, PhaseV has raised $15 million and grown its team to 23 people. The company’s platform offers a more data-driven approach to clinical trials, enabling the use of artificial intelligence to guide trial decisions and increase the likelihood of success. Dr. Pryluk points out that one of the major reasons for the failure of clinical trials is the lack of proper indications and inefficient trial execution. PhaseV aims to solve these issues by providing a solution that optimizes the process and maximizes benefits for both the trial participants and the broader healthcare system.

What Undercode Says:

PhaseV’s AI-powered platform represents a breakthrough in the optimization of clinical trials. While clinical trials are critical in determining the safety and effectiveness of new drugs, the failure rates are staggeringly high, with only 10% of trials achieving success. The current process, which involves trial-and-error, coupled with high costs and lengthy timeframes, significantly hampers the development of life-saving treatments.

PhaseV’s use of AI is a game-changer in this context. By guiding decisions based on data, the platform helps pharma companies and biotech firms avoid costly mistakes. Dr. Pryluk highlights that one of the primary reasons for clinical trial failure is choosing incorrect indications and poorly executed trials. These issues can be mitigated with AI tools that analyze data and predict which trials have the best chance of success. In doing so, PhaseV is not only improving the chances of getting life-saving drugs to market faster but also reducing the financial strain that often accompanies the drug development process.

The startup’s potential is further reinforced by its recent recognition as one of the Top 10 Israeli startups to watch out for in 2025. This accolade underscores the impact of their work in the field and suggests that PhaseV could be an industry leader in clinical development optimization in the years to come. By empowering pharmaceutical companies to make better decisions, PhaseV is contributing to a more sustainable and efficient healthcare landscape.

Furthermore, PhaseV’s AI solution aligns with the broader trend of AI’s growing role in the healthcare industry. Machine learning algorithms, big data analysis, and other AI-driven technologies are increasingly being integrated into various aspects of healthcare, from diagnostics to treatment planning. PhaseV’s application of AI in the clinical trials space is an exciting example of how technology can improve traditional processes and potentially revolutionize the way drugs and medical devices are tested and brought to market.

Fact Checker Results:

90% Failure Rate: The claim of a 90% failure rate in clinical trials aligns with industry standards. Clinical trials have long faced significant challenges in achieving success, and various studies have reported similar figures.
Time and Cost: The reported time frame of over 10 years and cost of $3 billion to bring a drug to market is consistent with estimates from pharmaceutical industry sources. The lengthy and expensive process remains a significant barrier to innovation.
AI in Clinical Trials: PhaseV’s focus on using AI to optimize clinical trials is in line with a growing trend of adopting AI in healthcare. Many experts agree that AI can help streamline processes, reduce errors, and increase the probability of success.